Clonotypic diversification of intratumoral T cells following sipuleucel-T treatment in prostate cancer subjects

Cancer Research

Volumn 76, Issue 13, 2016, Pages 3711-3718

  Sheikh, Nadeem ^a   Cham, Jason ^b   Zhang, Li ^b   DeVries, Todd ^a   Letarte, Simon ^c   Pufnock, Jeff ^a   Hamm, David ^d   Trager, James ^a   Fong, Lawrence ^b  

^a Dendreon   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Hospira Inc   (United States)

^d ADAPTIVE BIOTECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SIPULEUCEL T; T LYMPHOCYTE RECEPTOR; TISSUE EXTRACT;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CANCER IMMUNOTHERAPY; CELL TRANSPORT; CONTROLLED STUDY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTRATUMORAL T LYMPHOCYTE; MALE; MULTICENTER STUDY (TOPIC); NEXT GENERATION SEQUENCING; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE ANALYSIS; T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE; TREATMENT OUTCOME; ADULT; CANCER STAGING; CASE CONTROL STUDY; CLINICAL TRIAL; FOLLOW UP; IMMUNOLOGY; MULTICENTER STUDY; NEOADJUVANT THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT;

ADULT; CASE-CONTROL STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; TISSUE EXTRACTS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84977471602     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-3173     Document Type: Article

References (35)

1. Disis ML. Mechanismof action of immunotherapy. Semin Oncol 2014;41 Suppl 5:S3-13.
2. Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P. Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy 2011; 31:813-28.
3. Cha E, Fong L. Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol 2011;29:3677-85.
4. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 2011;17:4101-9.
5. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 2012;72:5209-18.
6. PROVENGE® (sipuleucel-T) prescribing information. Seattle, (WA): Dendreon Corporation. [accessed 2015 Jun 8; last revision 2014 Oct]. Available from: http://www.provenge.com/pdf/prescribing-information.pdf.
7. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
8. Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 2013; 62:137-47.
9. Fong L, De Vries T, Cham J, Zhang L, Frohlich M, Trager J, et al. Localization of sipuleucel-Texpanded T cell clones into tumors of treated prostate cancer patients [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract nr 2937.
10. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst 2014;106:dju268.
11. Babel N, Brestrich G, Gondek LP, Sattler A, Wlodarski MW, Poliak N, et al. Clonotype analysis of cytomegalovirus-specific cytotoxic T lymphocytes. J Am Soc Nephrol 2009;20:344-52.
12. Linnemann C, Mezzadra R, Schumacher TN. TCR repertoires of intratumoral T-cell subsets. Immunol Rev 2014;257:72-82.
13. Linnemann C, Heemskerk B, Kvistborg P, Kluin RJ, Bolotin DA, Chen X, et al. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med 2013;19:1534-41.
14. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
15. Postow MA, Manuel M, Wong P, Yuan J, Dong Z, Liu C, et al. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. J Immunother Cancer 2015;3:23.
16. Dziubianau M, Hecht J, Kuchenbecker L, Sattler A, Stervbo U, Rodelsperger C, et al. TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology. Am J Transplant 2013;13:2842-54.
17. Clinical Trials.gov. Neo ACT: an open label, phase 2 trial of immunotherapy with sipuleucel-T (Provenge®) as neoadjuvant treatment in men with localized prostate cancer. Available from: https://clinicaltrials.gov/show/NCT00715104.
18. DNeasy® Blood & Tissue Kit. Qiagen Inc., Valencia, CA. Available from: www.qiagen.com.
19. Robins H, Desmarais C, Matthis J, Livingston R, Andriesen J, Reijonen H, et al. Ultra-sensitive detection of rare T cell clones. J Immunol Methods 2012;375:14-9.
20. Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 2009;114:4099-107.
21. Carlson CS, Emerson RO, Sherwood AM, Desmarais C, Chung MW, Parsons JM, et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun 2013;4:2680.
22. Hill MO. Diversity and evenness: a unifying notation and its consequences. Ecology 1973;54:427-32.
23. Lau MK. Diversity Sampler: Functions for re-sampling a community matrix to compute diversity indices at different sampling levels. R package version 2.1. 2014. Available from:http://cran.r-project.org/web/packages/DiversitySampler/.
24. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: The R Foundation for Statistical Computing; 2015.
25. Wolda H. Similarity indices, sample size and diversity. Oecologia 1981; 50:296-302.
26. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
27. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388-97.
28. Madan RA, Gulley JL, Kantoff PW. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J 2013;19:50-8.
29. Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med 2014;6:238ra70.
30. Mulders PF, De Santis M, Powles T, Fizazi K. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immunother 2015;64: 655-63.
31. Guha Thakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ, et al. Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res 2015;21: 3619-30.
32. Laing KJ, Russell RM, Dong L, Schmid DS, Stern M, Magaret A, et al. Zoster vaccination increases the breadth of CD4+ T cells responsive to varicella zoster virus. J Infect Dis 2015;212:1022-31.
33. Ndhlovu ZM, Stampouloglou E, Cesa K, Mavrothalassitis O, Alvino DM, Li JZ, et al. The breadth of expandable memory CD8+ T cells inversely correlates with residual viral loads in HIV elite controllers. J Virol 2015;89:10735-47.
34. Rosario M, Bridgeman A, Quakkelaar ED, Quigley MF, Hill BJ, Knudsen ML, et al. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol 2010;40:1973-84.
35. Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010;15:969-75.